SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the ...

The S&P 500 Index ($SPX) (SPY) today is up +0.48%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.39%, and the Nasdaq ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Scientists have found that lithium orotate — which is different from the kind of lithium typically used to treat mental health conditions — not only stopped the brain disease in mice but also reversed ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.07 per share a year ago. These ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the Cambridge, ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...